Established in 2021 and headquartered in Chengdu Medical City, C-Ray Therapeutics (Chengdu) Co., Ltd. is dedicated to providing comprehensive services for the development and manufacturing of radiopharmaceuticals. The company operates a 28,000 m² facility that meets cGMP standards recognised by the FDA, EMA, and NMPA. Under China’s Class A Radiation Safety License, C-Ray can handle over 30 types of medical isotopes, supporting a wide range of radiopharmaceutical candidates from early research through to commercial supply.

Key Products and Services

• Radiopharmaceutical CRDMO Services: End-to-end solutions encompassing process development, preclinical studies, clinical trial material production, and commercial-scale manufacturing.
• Isotope Handling: Capabilities to operate with over 30 medical isotopes, including 68Ga, 64Cu, 18F, 89Zr, 177Lu, and 225Ac.
• Automated GMP Production Lines: Utilisation of China’s first fully automated GMP-grade radiopharmaceutical production line, ensuring efficiency, consistency, and product quality.
• Cold-Chain Logistics: Development of international-standard radiopharmaceutical cold-chain systems to address long-distance, multi-centre transport challenges.
• Comprehensive R&D Facilities: A GLP-like animal facility and multi-product manufacturing capabilities to support the full lifecycle of radiopharmaceutical development.

With a commitment to innovation and quality, C-Ray Therapeutics (Chengdu) Co., Ltd. continues to advance the field of radiopharmaceuticals. The company’s integrated services and state-of-the-art facilities position it as a key player in the global radiopharmaceutical industry, dedicated to providing effective and precise therapeutic solutions.